Cancer
Patients with a rare and aggressive form of liposarcoma need treatment advances
Mehdi Lahmar, Clinical Program Leader in Oncology at Boehringer Ingelheim discusses the role that our investigational MDM2-p53 antagonist plays in rare types of soft tissue sarcoma and the launch of the Brightline-1 clinical trial.
Read more
Cancer
Sarcoma: An expert’s perspective
Hear from Gary Schwartz, MD, Director of the Case Comprehensive Cancer Center, Cleveland, Ohio.
Read more
Cancer
Exploring T-cells in cancer
Lamine Mbow, our Global Head of Cancer Immunology and Immune Modulation, shares our approach to immuno-oncology highlighting our cancer research and how we are driving innovation to deliver meaningful advances to people with cancer.
Read more
Related press releases
August 27, 2024
Boehringer Ingelheim to unveil oncology research at WCLC
Links
TAKING CANCER ON
Episode 2: A Deep Dive Into Clinical Trials
TAKING CANCER ON
Episode 3: Collaborating Against Cancer
Human Health
Human Health partnering
Press Release
Boehringer Ingelheim signs license deal with A*STAR
Press Release
Boehringer Ingelheim Signs Option to Acquire Trutino Biosciences
Taking Cancer on: The Podcast
From early stage discovery to clinical trials and approval, we're Taking Cancer On. Click here to access the podcast homepage, where you will find all the available episodes.